DA-R-EPOCH versus R-CHOP in intermediate and high risk IPI diffuse large B-cell lymphoma, a randomized controlled trial

Mariam Shalaby; Hamdy Zawam; Wael Abdelgawad; Neamat Kassem; Mohamed El Ghobashy; Essam Ayad

doi:10.53730/ijhs.v6nS6.12359

Authors

Mariam Shalaby
Mariamshalaby@kasralainy.edu.eg
Assistant Lecturer, MSC, Clinical oncology department, Kasr Alainy School of Medicine, Cairo University, Egypt
Hamdy Zawam Professor, MD, Clinical oncology department, Kasr Alainy School of Medicine, Cairo University, Egypt
Wael Abdelgawad Assistant Professor, MD, Clinical oncology department, Kasr Alainy School of Medicine, Cairo University, Egypt
Neamat Kassem Professor, MD, Clinical pathology department, Kasr Alainy School of Medicine, Cairo University, Egypt
Mohamed El Ghobashy Lecturer, MD, Diagnostic and Interventional radiology department, Kasr Alainy School of Medicine, Cairo University, Egypt
Essam Ayad Professor, MD, Pathology department, Kasr Alainy School of Medicine, Cairo University, Egypt

Keywords:

Diffuse large B cell lymphoma (DLBCL), cell of origin, IPI, R-CHOP, DA-R-EPOCH

Abstract

Background: Diffuse large B-cell lymphoma is a challenging disease in management. Although most patients are cured with the standard R-CHOP, one third of them remains refractory to this regimen. As prognosis of refractory disease is worse than primarily responding one, several trials investigated other more intense frontline regimens tailored based upon risk and biological characteristics. Patients & Methodology: This is a prospective randomized trial investigating the more intensive DA-R-EPOCH regimen as frontline therapy in intermediate and high risk DLBCL patients in comparison to the standard R-CHOP regimen. We compared both regimens in these risk categories as well as undergoing a subgroup analysis according to cell of origin (Germinal center versus activated B cell) and according to BCL2 and C-myc expression (double expressor lymphoma). Toxicities in both arms have been analyzed according to common terminology criteria for adverse events (CTCAE). Results: In spite of being more toxic and complex, there was no significant improvement in DFS or response rate with DA-R-EPOCH. No significant benefit for DA-R-EPOCH over R-CHOP in both germinal center and activated B-cell DLBCL. Conclusion: Tailoring upfront treatment of DLBCL based upon risk classification or BCL2/c-myc expression remains an area of unanswered questions and warrants further investigations.

Downloads

Download data is not yet available.

References

Alizadeh AA, Eisen MB, Davis RE, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503–511.

Bartlett NL et al. (2019). Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol 2019 Apr 2

Beham-Schmid C. (2017). Aggressive lymphoma 2016: revision of the WHO classification. Memo. 2017;10(4):248-254

Coiffier B, Lepage E, Brière J, et al.(2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.

Dholaria B, Vishnu P, Roy V, Tun HW, Sher T, Rivera CE, Ailawadhi S, Diehl N, Hodge DO, Moreno‐Vanegas YA,(2017) DA.R-EPOCH Vs. R-CHOP for high-risk diffuse large b-cell lymphoma: the mayo clinic florida experience, Blood, 2017, 130.

Double hit lymphoma: The MD Anderson Cancer Center clinical experience. June 2014 British Journal of Haematology 166(6)

Kieron Dunleavy, Michelle A Fanale, (2018). Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study, Lancet 2018, vol 5, issue 12:e609-e617

Ko BS, Chen LJ, Huang HH, Wen YC, Liao CY, Chen HM, Hsiao FY. (2018). Subtype-specific epidemiology of lymphoid malignancies in Taiwan compared to Japan and the United States, 2002-2012. Cancer Med. 2018;7(11):5820–31.

Mafaldo-Gómez, D. A., & Reyes-Meza, O. B. (2022). Training in values in environmental education in high school students: Case study: Education, environment, and society. International Journal of Life Sciences, 6(2), 65–71. https://doi.org/10.53730/ijls.v6n2.10561

Mokhtar N., Cancer pathology registry (1998–2000). NationalCancer Institute. Cairo University

Rosenthal A, Younes A, Phoenix CA, Kettering S, York N (2017) High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev 31(2):37–42

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). The COVID-19 pandemic. International Journal of Health Sciences, 5(2), vi-ix. https://doi.org/10.53730/ijhs.v5n2.2937

Taylor M. Weis, Bernard L. Marini, Victoria R. Nachar, Anna M. Brown, Tycel J. Phillips, Julia Brown, Ryan A. Wilcox, Mark S. Kaminski, Sumana Devata & Anthony J. Perissinotti (2020) Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas, Leukemia & Lymphoma, 61:5, 1126-1132

Wang, F., Xu, Rh., Luo, Hy. et al. (2008). Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 8, 115 (2008)

Wardana, I. M., Ardani, I. G. A. I., Aryani, L. N. A., Windiani, I. G. A. T., Adnyana, I. G. N. S., & Setiawati, Y. (2022). Other mental disorders YDT due to brain damage and dysfunction and physical disease in patients with anti-NMDA encephalitis: Case report. International Journal of Health & Medical Sciences, 5(4), 267-271. https://doi.org/10.21744/ijhms.v5n4.1948

Xin Yu Zhang, Jin Hua Liang,Li Wang, Hua Yuan Zhu, Wei Wu1, Lei Cao, Lei Fan, Jian Yong Li, Wei Xu (2019). DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma. Journal of Cancer Research and Clinical Oncology (2019) 145:117–127